Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Reumatologia
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2523-31062020000100231 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2523-310620200001002312020-08-05Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal studyHorimoto,Alex Magno CoelhoJesus,Laize Guerreiro deSouza,Albert Schiaveto deRodrigues,Silvia HelenaKayser,Cristiane Systemic sclerosis Anti-annexin V Digital ulcers Vasculopathy Biomarkers Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease.info:eu-repo/semantics/openAccessSociedade Brasileira de ReumatologiaAdvances in Rheumatology v.60 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231en10.1186/s42358-020-00140-w |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Horimoto,Alex Magno Coelho Jesus,Laize Guerreiro de Souza,Albert Schiaveto de Rodrigues,Silvia Helena Kayser,Cristiane |
spellingShingle |
Horimoto,Alex Magno Coelho Jesus,Laize Guerreiro de Souza,Albert Schiaveto de Rodrigues,Silvia Helena Kayser,Cristiane Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
author_facet |
Horimoto,Alex Magno Coelho Jesus,Laize Guerreiro de Souza,Albert Schiaveto de Rodrigues,Silvia Helena Kayser,Cristiane |
author_sort |
Horimoto,Alex Magno Coelho |
title |
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
title_short |
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
title_full |
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
title_fullStr |
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
title_full_unstemmed |
Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
title_sort |
anti-annexin v autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study |
description |
Abstract Background: Annexins are a group of conserved proteins which exert several regulatory functions on various cellular activities. Increased frequency and levels of antibodies against annexin V have already been observed in several autoimmune diseases including systemic sclerosis (SSc), but their role as a vascular biomarker is unknown. The aim of this study was to determine the serum levels and the dynamical behavior of anti-annexin V antibodies over a 24 months follow-up in patients with SSc. Methods: In this bicentric cross-sectional study, 70 patients with SSc were consecutively selected from March 2016 to April 2017. Demographic and clinical features, including the presence of active DUs, were collected. Serum anti-annexin V IgG and IgM antibodies were measured at baseline and after 6, 12 and 24 months of follow-up. Videocapillaroscopy was performed in all patients. Results: Among the 70 SSc patients included anti-annexin V IgG was found in 11 patients (15.7%) (range of 15.88–39.48 U/mL) and anti-annexin V IgM in 10 patients (14.3%) (range of 14.16-22.69 U/mL) at baseline. During follow-up, the number of patients who were positive for anti-annexin V IgG and IgM remained stable over 24 months. Among the patients with positive anti-annexin V IgG at baseline the frequency of patients with necrosis or amputation of extremities, forced vital capacity less than 70% and pulmonary arterial hypertension (PAH) was significantly higher than in patients with negative anti-annexin V IgG antibodies. Patients with anti-annexin V IgG had also a higher Raynaud's Condition Score and a higher Health Assessment Questionnaire Disability Index (HAQ-DI) than patients without these antibodies at baseline. Patients with positive anti-annexin V IgM at baseline presented a higher frequency of PAH, compared to those with negative anti-annexin V IgM at baseline. Conclusions: Anti-annexin V antibodies are stable and do not change their positivity during a 24 month follow-up in SSc patients. Anti-annexin V IgG was associated with more severe interstitial lung involvement and digital microangiopathy, and patients with anti-annexin V IgG or IgM had a higher occurrence of PAH indicating an association of these biomarker with more severe disease. |
publisher |
Sociedade Brasileira de Reumatologia |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062020000100231 |
work_keys_str_mv |
AT horimotoalexmagnocoelho antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy AT jesuslaizeguerreirode antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy AT souzaalbertschiavetode antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy AT rodriguessilviahelena antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy AT kaysercristiane antiannexinvautoantibodiesandvascularabnormalitiesinsystemicsclerosisalongitudinalstudy |
_version_ |
1756441906741510144 |